Aspire Biopharma Holdings (ASBP) Interest & Investment Income (2022 - 2024)
Aspire Biopharma Holdings (ASBP) posted quarterly Interest & Investment Income of $169912.0 for Q2 2024, down 91.91% year-over-year from $2.1 million in Q3 2023, and down 27.65% quarter-over-quarter from $234853.0 in Q1 2024.
Aspire Biopharma Holdings (ASBP) Interest & Investment Income (2022 - 2024) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Interest & Investment Income for 3 consecutive years, with $169912.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Interest & Investment Income fell 91.91% year-over-year to $169912.0; the TTM figure through Jun 2024 stood at $920917.0 (down 89.96% YoY), while the FY2024 annual figure was $548676.0, down 90.56% from the prior year.
- Interest & Investment Income declined to $169912.0 in Q2 2024 per ASBP's latest filing, from $234853.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $3.2 million in Q1 2023 and bottomed at $21393.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $1.1 million across 3 years, with a median of $339600.5 in 2022.
- Annual changes were most pronounced in 2023 — Interest & Investment Income soared 14844.13% — and 2024, when it sank 92.65%.
- Aspire Biopharma Holdings' Interest & Investment Income stood at $2.5 million in 2022, then slumped by 89.75% to $260668.0 in 2023, then sank by 34.82% to $169912.0 in 2024.
- Business Quant data shows ASBP's Interest & Investment Income at $169912.0 in Q2 2024, $234853.0 in Q1 2024, and $260668.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 169,912.00 |
| Mar 31, 2024 | 234,853.00 |
| Dec 31, 2023 | 260,668.00 |
| Sep 30, 2023 | 255,484.00 |
| Jun 30, 2023 | 2.10 Mn |
| Mar 31, 2023 | 3.20 Mn |
| Dec 31, 2022 | 2.54 Mn |
| Sep 30, 2022 | 1.33 Mn |
| Jun 30, 2022 | 418,533.00 |
| Mar 31, 2022 | 21,393.00 |